Literature DB >> 27507598

Neuroprotective effects of antibodies on retinal ganglion cells in an adolescent retina organ culture.

Katharina Bell1, Corina Wilding1, Sebastian Funke1, Natarajan Perumal1, Sabine Beck1, Dominik Wolters1, Jana Holz-Müller1, Norbert Pfeiffer1, Franz H Grus2.   

Abstract

Glaucoma, a neurodegenerative disease, is characterized by a progressive loss of retinal ganglion cells (rgc). Up- and down-regulated autoantibody immunoreactivities in glaucoma patients have been demonstrated. Previous studies showed protective effects of down-regulated antibodies [gamma (γ)-synuclein and glial fibrillary acidic protein [GFAP]) on neuroretinal cells. The aim of this study was to test these protective antibody effects on rgc in an organ culture model and to get a better understanding of cell-cell interactions of the retina in the context of the protective effect. We used an adolescent retinal organ culture (pig) with an incubation time of up to 4 days. Retinal explants were incubated with different antibodies for 24 h (anti-GFAP, anti-γ-synuclein and anti-myoglobin antibody as a control). Brn3a and TUNEL staining were performed. We also conducted glutamine synthetase staining and quantification of the retinal explants. Mass spectrometry analyses were performed as well as protein analyses via microarray. We detected a continuous decrease of rgc/mm in the retinal explants throughout the 4 days of incubation with increased TUNEL rgc staining. Immunohistochemical analyses showed a protective effect of anti-γ-synuclein (increased rgc/mm of 41%) and anti-GFAP antibodies (increased rgc/mm of 37%). Mass spectrometric, microarray and immunohistochemical analyses demonstrated Müller cell involvement and decreased endoplasmic reticulum stress response in the antibody-treated retinae. We could detect that the tested antibodies have a protective effect on rgc which seems to be the result of reduced stress levels in the retina as well as a shift of glutamine synthetase localization in the endfeet of the Müller cells towards the inner retinal layer. Loss of retinal ganglion cells (rgc) in glaucoma leads to blindness. Several antibodies are down-regulated in glaucoma patients. Our aim was to test if these antibodies have a protective effect of rgc in a retinal organ culture. This could be shown with an increase of rgc numbers. This effect results through reduced stress levels and the shift of glutamine synthetase localization.
© 2016 International Society for Neurochemistry.

Entities:  

Keywords:  zzm321990GFAPzzm321990; antibody; autoimmunity; glaucoma; retinal explant; γ-synuclein

Mesh:

Substances:

Year:  2016        PMID: 27507598     DOI: 10.1111/jnc.13765

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  11 in total

1.  Biomarkers for glaucoma: from the lab to the clinic.

Authors:  N Von Thun Und Hohenstein-Blaul; S Kunst; N Pfeiffer; F H Grus
Journal:  Eye (Lond)       Date:  2017-01-13       Impact factor: 3.775

2.  Valproic Acid Reduces Neuroinflammation to Provide Retinal Ganglion Cell Neuroprotection in the Retina Axotomy Model.

Authors:  James R Tribble; Elizabeth Kastanaki; A Berşan Uslular; Carola Rutigliani; Tim J Enz; Pete A Williams
Journal:  Front Cell Dev Biol       Date:  2022-05-12

3.  A Monoclonal Anti-HMGB1 Antibody Attenuates Neurodegeneration in an Experimental Animal Model of Glaucoma.

Authors:  Henrik Tonner; Selina Hunn; Nadine Auler; Carsten Schmelter; Vanessa M Beutgen; Harald D von Pein; Norbert Pfeiffer; Franz H Grus
Journal:  Int J Mol Sci       Date:  2022-04-07       Impact factor: 6.208

4.  Decelerated neurodegeneration after intravitreal injection of α-synuclein antibodies in a glaucoma animal model.

Authors:  J Teister; F Anders; S Beck; S Funke; H von Pein; V Prokosch; N Pfeiffer; F Grus
Journal:  Sci Rep       Date:  2017-07-24       Impact factor: 4.379

Review 5.  Modulation of the Immune System for the Treatment of Glaucoma.

Authors:  Katharina Bell; Nadine von Thun Und Hohenstein-Blaul; Julia Teister; Franz Grus
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

6.  Neuroprotective and neuroregenerative effects of CRMP-5 on retinal ganglion cells in an experimental in vivo and in vitro model of glaucoma.

Authors:  Jasmin Lauzi; Fabian Anders; Hanhan Liu; Norbert Pfeiffer; Franz Grus; Solon Thanos; Stefan Arnhold; Verena Prokosch
Journal:  PLoS One       Date:  2019-01-23       Impact factor: 3.240

7.  Comparison of Two Solid-Phase Extraction (SPE) Methods for the Identification and Quantification of Porcine Retinal Protein Markers by LC-MS/MS.

Authors:  Carsten Schmelter; Sebastian Funke; Jana Treml; Anja Beschnitt; Natarajan Perumal; Caroline Manicam; Norbert Pfeiffer; Franz H Grus
Journal:  Int J Mol Sci       Date:  2018-12-03       Impact factor: 5.923

8.  Synthetic Polyclonal-Derived CDR Peptides as an Innovative Strategy in Glaucoma Therapy.

Authors:  Carsten Schmelter; Kristian Nzogang Fomo; Natarajan Perumal; Caroline Manicam; Katharina Bell; Norbert Pfeiffer; Franz H Grus
Journal:  J Clin Med       Date:  2019-08-15       Impact factor: 4.241

9.  Establishing a Surgical Procedure for Rhesus Epiretinal Scaffold Implantation with HiPSC-Derived Retinal Progenitors.

Authors:  Ziming Luo; Kang Li; Kaijing Li; Bikun Xian; Ying Liu; Sijing Yang; Chaochao Xu; Zhigang Fan; Shoutao Lu; Haijun Zhang; Jian Ge
Journal:  Stem Cells Int       Date:  2018-04-15       Impact factor: 5.443

Review 10.  Antibody and Protein Profiles in Glaucoma: Screening of Biomarkers and Identification of Signaling Pathways.

Authors:  Nadine Auler; Henrik Tonner; Norbert Pfeiffer; Franz H Grus
Journal:  Biology (Basel)       Date:  2021-12-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.